<DOC>
	<DOCNO>NCT00686777</DOCNO>
	<brief_summary>The objective evaluate efficacy safety combination therapy subcutaneous ( SC ) Pegylated Interferon ( PEG-IFN ) alfa-2b 1.5 ug/kg/week plus low-dose ribavirin administer 48 week participant chronic hepatitis C virus ( HCV ) infect HCV genotype 1 high viral load , weigh 50 kg less .</brief_summary>
	<brief_title>Pegylated Interferon ( PEG-IFN ) Alfa-2b Low Dose Ribavirin Treatment Chronic Hepatitis C Patients With Genotype 1 High Viral Load Low Body Weight ( Study P05172 ) ( COMPLETED )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<criteria>Diagnosed chronic hepatitis C. Minimum 20 year age Willing use adequate contraception course study . Participants hospitalize least 14 day since treatment initiation . Positive HCV genotype 1 ( genotype 1a 1b ) high viral load ( HCVRNA &gt; =100 kIU/mL ) . Participants weigh 40 kg 50 kg . Hematology result : hemoglobin level &gt; =12 g/dL neutrophil &gt; =1,500/mm^3 platelet &gt; =100,000/mm^3 Previous ribavirin therapy . Previous interferon therapy within 90 day registration . Participants receive treatment injectable product contain glycyrrhizin/cysteine/glycine ( Stronger NeoMinophagen C , etc . ) , Shosaikoto , ursodeoxycholic acid within 30 day start treatment Participants receive treatment antiviral antitumor drug receive immunomodulating therapy ( include steroid radiotherapy ) within 90 day start treatment [ exclude local administration topical drug ] . Participants receive investigational drug within 180 day start treatment . Hepatitis Bs ( HBs ) antigenpositive Antinuclear antibody &gt; =1:160 Fasting blood glucose &gt; =110 mg/dL ( however , participant fast blood glucose 110 mg/dL &lt; 126 mg/dL register HbA1c &lt; 6.5 % ) Participants diagnose liver cirrhosis recent celioscopy liver biopsy . Participants history follow : liver failure ; hepatic encephalopathy , esophageal varix , ascites ; depression schizophrenia require treatment suicidal attempt ideation ; epileptic seizure require drug treatment ; autoimmune disease ( Hashimoto 's disease , Crohn 's disease , ulcerative colitis , chronic rheumatoid arthritis , idiopathic thrombocytopenic purpura , systemic erythematosus , autoimmune hemolytic anemia , scleroderma ) ; hepatic cancer Participants follow : liver disease autoimmune hepatitis , alcoholic liver disease , druginduced hepatic impairment ; hemophilia ; arrhythmia require treatment participant history angina pectoris , cardiac failure , myocardial infarction , lifethreatening arrhythmia ; hypertension ( systolic BP 160 mmHg diastolic BP 100 mmHg ) possible control drug therapy ; chronic pulmonary disease ; hemoglobinopathy ( thalassemia , sickle cell anemia ) ; malignant tumor history malignant tumor within past 5 year ; thyroid function disorder control drug therapy . Participants organ transplant ( exclude cornea hair transplant ) . Participants history hypersensitivity interferon preparation , nucleoside analog , biological product vaccine . Participants specific response PEGIFN alfa2b prick test conduct initiation treatment . Participants pregnant nursing ( case male Participants : partner pregnant )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hepatitis C</keyword>
</DOC>